Vitamin B3 (Niacin) — Research Profile

Both are forms of vitamin B3 but have different effects. Niacin (nicotinic acid) affects cholesterol by raising HDL and lowering LDL/triglycerides, but causes flushing. Niacinamide (nicotinamide) does not affect cholesterol and does not cause flushing, but supports skin health and has shown cancer prevention benefits. Both contribute to NAD+ production.

NR is a newer form of vitamin B3 that efficiently raises NAD+ levels, a coenzyme that declines with age. Human trials show NR at 250-1,000 mg/day increases blood NAD+ by 40-90%. While animal studies show promising anti-aging effects, large human clinical trials on healthspan and lifespan outcomes are still ongoing. It is well-tolerated but expensive compared to standard B3 forms.

To minimize niacin flush: start with a low dose (100 mg) and gradually increase over weeks, take with food, take aspirin (325 mg) 30 minutes before, and use immediate-release rather than sustained-release niacin (which has more liver risk). Alternatively, niacinamide and NR provide B3 benefits without any flushing.

There is no single best form; it depends on the goal. Nicotinic acid is the form that alters blood lipids but causes flushing, nicotinamide (niacinamide) delivers the vitamin without flushing and is the form shown to reduce new skin cancers in high-risk patients, and nicotinamide riboside is used specifically to raise NAD+ levels. For meeting basic requirements any of these supplies the vitamin, so the form choice is driven by the specific outcome you want rather than by potency.

The firmly established benefit is preventing and treating niacin deficiency (pellagra). Pharmacologic nicotinic acid measurably improves blood lipids, raising HDL cholesterol by 10-30%, lowering LDL by 10-25% and triglycerides by 20-50%, yet in trials this did not translate into fewer cardiovascular events when added to statin therapy. In dermatology, oral nicotinamide reduced the rate of new non-melanoma skin cancers in high-risk patients in a phase 3 trial.

The adult RDA is 16 mg niacin equivalents per day for men and 14 mg NE for women, rising to 18 mg NE in pregnancy and 17 mg NE during lactation. For niacin from supplements and fortified foods the tolerable upper limit is 35 mg/day in adults. The gram-level doses used for lipid management (roughly 1,000-3,000 mg/day of nicotinic acid) are prescription-scale and require medical supervision, not routine self-dosing.

For meeting the RDA, time of day does not matter and no head-to-head timing studies exist. The timing that does matter is with immediate-release nicotinic acid, which is commonly taken with food to blunt flushing. Because nicotinamide and nicotinamide riboside do not cause flushing, their timing is flexible.

The hallmark side effect is flushing with burning, tingling and itching, which nicotinic acid causes at 30-50 mg or more; nicotinamide and nicotinamide riboside do not typically flush. At high therapeutic doses nicotinic acid can raise blood glucose and, over months to years, damage the liver, while nicotinamide around 3,000 mg/day can cause nausea, vomiting and signs of liver toxicity. In a controlled trial, chronic nicotinamide riboside was well tolerated at the doses tested.

Yes, mainly at pharmacologic doses. Large doses of nicotinic acid can raise blood glucose, so people on diabetes medications may need monitoring and dose adjustment. Adding high-dose nicotinic acid to statin therapy gave no extra cardiovascular benefit in a large trial. Separately, the tuberculosis drugs isoniazid and pyrazinamide interfere with the body's production of niacin from tryptophan.

Most people meet their needs from food, so supplementation is aimed at those at risk of deficiency: people with undernutrition, alcohol use disorder, AIDS, inflammatory bowel disease, or liver cirrhosis, plus those with inherited conditions such as Hartnup disease or carcinoid syndrome. Beyond correcting deficiency, gram-level nicotinic acid for lipids or nicotinamide for skin-cancer prevention are clinical decisions made with a physician rather than general-wellness choices.

It depends entirely on the form and the goal. The skin flushing from immediate-release nicotinic acid appears within roughly 30 minutes of a dose of 30-50 mg or more. Lipid changes from pharmacologic nicotinic acid build over weeks of daily use, while nicotinamide riboside raised blood NAD+ levels over weeks of daily dosing in healthy adults. For frank niacin deficiency (pellagra), the WHO-recommended nicotinamide treatment course runs 3-4 weeks, and no reliable symptom-resolution timeline is established in the cited sources.

At nutritional intakes the tolerable upper intake level for supplemental or fortified niacin is 35 mg/day for adults, and staying at or below that is well established as safe. Pharmacologic nicotinic acid at 1,000-3,000 mg/day taken over months to years can be hepatotoxic, and extended-release formulations carry the greatest liver-toxicity risk; nicotinamide can also cause liver toxicity at intakes around 3,000 mg/day. Gram-level dosing should only be used under medical supervision with liver-function monitoring.

Yes. The adult tolerable upper intake level is 35 mg/day for niacin added to supplements or fortified foods, a limit set because 30-50 mg or more of nicotinic acid triggers flushing, burning, tingling and itching. That upper limit does not apply to gram-level nicotinic acid prescribed and monitored by a clinician. At much higher intakes toxicity becomes serious: nicotinamide around 3,000 mg/day can cause nausea, vomiting and signs of liver damage.

Nutritional-dose niacin is routinely included in B-complex and multivitamin products without a problem. The meaningful cautions apply to pharmacologic doses rather than to stacking supplements: high-dose nicotinic acid added on top of statin therapy produced no additional cardiovascular benefit in a large trial. If you take gram-level nicotinic acid, it should be managed by a clinician rather than self-combined.

Read the label for the specific form, because they behave very differently: nicotinic acid (also labeled niacin) causes flushing and is the lipid-active form, nicotinamide/niacinamide does not flush, and nicotinamide riboside is marketed to raise NAD+. Note whether it is immediate- or extended-release, since extended-release nicotinic acid carries the highest liver-toxicity risk. For general nutrition, a dose near the 16 mg/day (men) or 14 mg/day (women) RDA is sufficient, and everyday supplements at or under the 35 mg/day upper limit avoid flushing.